These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 2177568)

  • 1. Recent developments in the management of emesis with the 5-HT3 antagonist granisetron.
    Button D
    Semin Oncol Nurs; 1990 Nov; 6(4 Suppl 1):14-9. PubMed ID: 2177568
    [No Abstract]   [Full Text] [Related]  

  • 2. 5-HT3 receptor antagonists, a new approach in emesis: a review of ondansetron, granisetron and tropisetron.
    Seynaeve C; Verweij J; de Mulder PH
    Anticancer Drugs; 1991 Aug; 2(4):343-55. PubMed ID: 1665723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Granisetron (BRL 43694) in the treatment of cytostatic drug-induced emesis: a summary.
    Pintens H
    Cancer Treat Rev; 1990 Sep; 17(2-3):307-10. PubMed ID: 2176932
    [No Abstract]   [Full Text] [Related]  

  • 4. Antiemetic control: 5-HT3 antagonists: review of clinical results, with particular emphasis on ondansetron.
    Kidgell AE; Butcher ME; Brown GW
    Cancer Treat Rev; 1990 Sep; 17(2-3):311-7. PubMed ID: 2176933
    [No Abstract]   [Full Text] [Related]  

  • 5. Review of experience with ondansetron and granisetron.
    Aapro MS
    Ann Oncol; 1993; 4 Suppl 3():9-14. PubMed ID: 8395875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 5-HT3-receptor antagonists in the control of delayed-onset emesis.
    Gridelli C
    Anticancer Res; 2003; 23(3C):2773-82. PubMed ID: 12926112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The symptomatic control of cytostatic drug-induced emesis. A recent history and review.
    Joss RA; Brand BC; Buser KS; Cerny T
    Eur J Cancer; 1990; 26 Suppl 1():S2-8. PubMed ID: 2169781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The budgetary impact of 5-HT3 receptor antagonists in the management of chemotherapy-induced emesis.
    Jones AL; Lee GJ; Bosanquet N
    Eur J Cancer; 1992; 29A(1):51-6. PubMed ID: 1332738
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First choice for radiation-induced nausea and vomiting--the efficacy and safety of granisetron.
    Goldsmith B
    Acta Oncol; 2004 Sep; 43 Suppl 15():19-22. PubMed ID: 15370626
    [No Abstract]   [Full Text] [Related]  

  • 10. 5-HT3-receptor antagonists: a review of pharmacology and clinical efficacy.
    Cunningham RS
    Oncol Nurs Forum; 1997 Aug; 24(7 Suppl):33-40. PubMed ID: 9282379
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Granisetron. A review of its pharmacological properties and therapeutic use as an antiemetic.
    Plosker GL; Goa KL
    Drugs; 1991 Nov; 42(5):805-24. PubMed ID: 1723376
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical studies with granisetron, a new 5-HT3 receptor antagonist for the treatment of cancer chemotherapy-induced emesis. The Granisetron Study Group.
    Joss RA; Dott CS
    Eur J Cancer; 1993; 29A Suppl 1():S22-9. PubMed ID: 8381293
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I/II trial of granisetron: a novel 5-hydroxytryptamine antagonist for the prevention of chemotherapy-induced nausea and vomiting.
    Addelman M; Erlichman C; Fine S; Warr D; Murray C
    J Clin Oncol; 1990 Feb; 8(2):337-41. PubMed ID: 2153767
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of granisetron, a selective 5-HT3 receptor antagonist, on ouabain-induced emesis in ferrets.
    Endo T; Sugawara J; Nemoto M; Minami M; Blower PR
    Res Commun Mol Pathol Pharmacol; 1998 Dec; 102(3):227-39. PubMed ID: 10342910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized trial of two doses of granisetron in the treatment of chemotherapy-induced emesis. Dutch results within a multinational study.
    Bots MW; Dijkstra HJ; Blijham GH; van der Wall E; Fehmers MC; Keizer HJ; Nortier JW; Siegenbeek van Heukelom L; Slee PH; Veenhof CH
    Neth J Med; 1992 Jun; 40(5-6):221-6. PubMed ID: 1331830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 5-hydroxytryptamine-3 antagonists: a new class of potent antiemetics in cancer therapy.
    Soukop M
    Recent Results Cancer Res; 1991; 121():86-90. PubMed ID: 1650016
    [No Abstract]   [Full Text] [Related]  

  • 17. Are all 5-HT3 receptor antagonists the same?
    Andrews PL; Bhandari P; Davey PT; Bingham S; Marr HE; Blower PR
    Eur J Cancer; 1992; 28A Suppl 1():S2-6. PubMed ID: 1320915
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is there a pharmacological basis for differences in 5-HT3-receptor antagonist efficacy in refractory patients?
    de Wit R; Aapro M; Blower PR
    Cancer Chemother Pharmacol; 2005 Sep; 56(3):231-8. PubMed ID: 15838653
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Superiority of granisetron to dexamethasone plus prochlorperazine in the prevention of chemotherapy-induced emesis.
    Warr D; Willan A; Fine S; Wilson K; Davis A; Erlichman C; Rusthoven J; Lofters W; Osoba D; Laberge F
    J Natl Cancer Inst; 1991 Aug; 83(16):1169-73. PubMed ID: 1653363
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effects of oral 5-HT3 antagonists on chemotherapy-induced emesis in patients with gynecologic cancers].
    Ishioka S; Sagae S; Saito T; Kiya T; Sugimura M; Akutagawa N; Umemura K; Ito E; Kudo R
    Gan To Kagaku Ryoho; 2000 Apr; 27(4):593-8. PubMed ID: 10791002
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.